OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Dr. Schuchter on Managing Ipilimumab's Side Effects

July 13th 2011

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Dr. Cella on Patient-Reported Outcomes in a Clinical Setting

July 12th 2011

Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Rini Explains the Axitinib Integration Process

July 11th 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process

Dr. Whelan on the Women the MA.20 Trial Benefits

July 11th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits

Dr. Whelan Discusses the MA.20 Trial's Survival Findings

July 8th 2011

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Dr. Lichter on ASCO's Global Collaboration Focus

July 8th 2011

Dr. Allen S. Lichter Chief Executive Officer (CEO) of the American Society of Clinical Oncology on ASCO's Global Collaboration Focus

Dr. Kris on Integrating Driver Mutation Testing Study Results

July 8th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results

Dr. West on NSCLC Afatinib and Cetuximab Combination

July 7th 2011

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Rini Describes Axitinib's and Sorafenib's Side Effects

July 6th 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Axitinib's and Sorafenib's Side Effects

Dr. Cella on the Value of Patient-Reported Outcomes

July 6th 2011

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Value of Patient-Reported Outcomes

Dr. Joensuu Discusses Resistance to Imatinib in GIST

July 5th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

Dr. Kris Talks About Defining Biomarkers

July 5th 2011

Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers

Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus

July 1st 2011

Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Dr. Kris Describes the Genetic Mutation Screening Study

June 30th 2011

Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study